Crypto & Forex April 1, 2026 0 Comments

Biogen’s Stock is Poised to Skyrocket — Here’s Why $202.41 Could Be Just the Beginning!

Ever find yourself wondering if a stock’s chart can tell you a story as gripping as a thriller novel? Take Biogen (BIIB), for example—a biotech powerhouse tackling some of the toughest neurological challenges out there, like multiple sclerosis and Alzheimer’s. Since mid-2025, this stock has been dancing along a beautifully clean, up-sloping trendline that’s as reliable as your morning coffee. And no, it’s not just a lucky streak — every time BIIB dips back to that line, it bounces right back up, signaling some serious, sustained demand lurking just beneath the surface. Yesterday’s close at $183.33 wasn’t just a number; it was the stock finding its footing after stepping back from January’s highs near $202, readying itself for the next surge. It’s like watching a coiled spring, packed with potential energy, waiting to launch. The spotlight is on $202.41, the next big milestone that BIIB seems hell-bent on reaching. As long as the stock respects this trendline, that’s where it’s headed. But if it breaks that line decisively, well, the story could twist—and I’ll be watching closely. Curious to see how this plays out? LEARN MORE.

Look at the chart of Biogen (BIIB), the biotechnology company focused on treatments for neurological diseases including multiple sclerosis and Alzheimer’s, and you’ll notice it has been riding an up-sloping trendline since the middle of 2025. That trendline has been one of the cleaner structures I’ve seen on a daily chart in a while. Price has touched it, respected it, and bounced off it on multiple occasions. That’s not coincidence. That tells me there is real, sustained demand underneath this stock every time it pulls back to that rising support.

BIIB closed yesterday at $183.33. The pullback from the January highs near $202 did exactly what it was supposed to do — it came back into the trendline, found its footing, and now the chart is coiling for the next move. That’s just what these things do in a healthy uptrend. The structure was never damaged. Price reclaimed the area it needed to and the trendline held.

The destination on this chart is $202.41. The trendline has been doing its job for months, and that’s exactly where price wants to go next. Probabilities are dictating that as long as BIIB does not close beneath the up-sloping trendline on a daily basis, the path of least resistance is back toward that level. A confirmed daily close above $202.41 opens the door to continuation beyond it.

Watch that trendline closely on any near-term weakness. If price closes below it with confirmation, the setup changes — but right now, the trendline is doing its job and $202.41 is the next stop.